Monitor Dr. Reddy's upcoming quarterly filings for initial Zytorvi ESCC prescription uptake and revenue contribution. The approval expands the immuno-oncology pipeline but near-term financial impact is unquantifiable without pricing or volume guidance.
Price Chart
Executive Summary
Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC) in India. This is the second approved indication for Zytorvi in India, following its November 2024 launch for nasopharyngeal carcinoma. The approval expands the addressable patient population for Dr. Reddy's immuno-oncology portfolio in a high-need indication where ESCC accounts for ~80% of esophageal cancer cases in India.
Key Facts
- CDSCO/DCGI approved Zytorvi (toripalimab) + cisplatin + paclitaxel for first-line unresectable advanced/recurrent/metastatic ESCC in adults
- Approval does not require PD-L1 expression-based patient selection
- Second approved indication in India after nasopharyngeal carcinoma (launched Nov 2024)
- Phase 3 JUPITER-06 trial showed 42% reduction in risk of disease or death vs chemo alone; median OS 17.7 months vs 12.9 months
- Dr. Reddy's holds exclusive rights to develop/commercialize toripalimab in 21 countries via 2023 licensing agreement with Junshi Biosciences
- Esophageal cancer was 4th leading cause of cancer death in India in 2024 (~8.1% of all cancer deaths)
Financial Impact
No financial terms or revenue guidance disclosed; ESCC represents a large addressable market in India but commercial ramp timeline and pricing are unstated
Risk Factors
- Competition from existing PD-1/PD-L1 therapies in India (Keytruda, Opdivo, etc.)
- Pricing and reimbursement dynamics in the Indian market may limit revenue potential
- Commercial execution risk in expanding to a new indication
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000715 |
| Document: 0001575872-26-000715-index.html | 0001575872-26-000715 |
| Document: 0001575872-26-000715.txt | 0001575872-26-000715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $13.65 | awaiting T+5 | — | $13.75 (+0.73%) |
Oct 26, 2026 today | 6-K | $13.65 | awaiting T+5 | — | $13.75 (+0.73%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.75 (−4.09%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.75 (+4.09%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.75 (+4.09%) |
Oct 23, 2026 3d ago | 6-K | $13.21 | awaiting T+5 | — | $13.75 (−4.09%) |
Oct 21, 2026 5d ago | 6-K | $13.19 | awaiting T+5 | — | $13.75 (+4.25%) |
Oct 14, 2026 12d ago | 6-K | $12.75 $13.19 | ▲ +3.45% | ▲ +3.00% | $13.75 (+7.84%) |
Oct 8, 2026 18d ago | 6-K | $12.20 $12.90 | ▲ +5.74% | ▲ +6.01% | $13.75 (+12.70%) |
Oct 7, 2026 19d ago | 6-K | $12.27 $12.75 | ▲ +3.91% | ▲ +4.89% | $13.75 (+12.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers